Cite
HARVARD Citation
Taniguchi, H. et al. (2023). Pan‐HER inhibitors overcome lorlatinib resistance caused by NRG1/HER3 activation in ALK‐rearranged lung cancer. Cancer science. 114 (1), pp. 164-173. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Taniguchi, H. et al. (2023). Pan‐HER inhibitors overcome lorlatinib resistance caused by NRG1/HER3 activation in ALK‐rearranged lung cancer. Cancer science. 114 (1), pp. 164-173. [Online].